Which hedge funds own RYTM? RHYTHM PHARMACEUTICALS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
11 of the hedge funds tracked by WhaleCreep disclosed a position in RYTM (RHYTHM PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $1.1bn in total. The largest holder by portfolio weight is RA Capital Management at 6.4% of its book. 1 manager opened a new position this quarter: Duquesne Family Office LLC. 1 exited: Brevan Howard Capital Management.
11tracked managers holding
1opened this quarter
1exited this quarter
Which hedge funds hold RYTM? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| RA Capital Management | Q2 2026 | 6.4% | $740.2m | 6,666,837 | 0% | held |
| Duquesne Family Office LLC | Q2 2026 | 0.5% | $22.6m | 203,618 | – | new |
| Woodline Partners | Q2 2026 | 0.3% | $84.3m | 758,891 | 0% | held |
| Citadel Advisors | Q2 2026 | 0.1% | $140.3m | 1,263,652 | -11% | reduced |
| Point72 Asset Management LP | Q2 2026 | 0.1% | $46.0m | 414,210 | -51% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $35.2m | 316,719 | -30% | reduced |
| WCM Investment Management | Q2 2026 | 0.0% | $8.9m | 80,552 | -0% | held |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $7.6m | 68,281 | -74% | reduced |
| Tudor Investment | Q2 2026 | 0.0% | $1.5m | 13,886 | -29% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $3.3m | 30,168 | -8% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $907.6k | 8,174 | -15% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Brevan Howard Capital Management | 0.0% | $328.5k |
How has hedge fund ownership of RYTM changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 11 | $1.1bn |
| Q1 2026 | 11 | $916.5m |
| Q4 2025 | 5 | $874.6m |
| Q3 2025 | 5 | $726.8m |
| Q2 2025 | 6 | $436.4m |
| Q1 2025 | 5 | $342.3m |
| Q4 2024 | 3 | $363.0m |
| Q3 2024 | 4 | $347.0m |
| Q2 2024 | 3 | $265.5m |
| Q1 2024 | 3 | $239.0m |
| Q4 2023 | 3 | $248.7m |
| Q3 2023 | 4 | $143.9m |
| Q2 2023 | 3 | $103.2m |
| Q1 2023 | 4 | $159.4m |
| Q4 2022 | 2 | $270.1m |
| Q3 2022 | 3 | $149.5m |
Counts every tracked manager that disclosed RYTM in that quarter's filing, including managers that have since stopped filing.